Loading...
Market
What percentage of infants will be successfully treated with the new oral immunotherapy for peanut allergies in Australia by the end of 2024?
2
Resolution / Starting Odds
Less than 50% • 25%
50% to 75% • 25%
76% to 90% • 25%
More than 90% • 25%
Official reports from Australian health authorities or published studies
Story
Australia Introduces World-First Oral Immunotherapy for Babies with Peanut Allergy
Jul 31, 2024, 02:04 AM
Australia has initiated a groundbreaking peanut allergy treatment for babies, marking the first time oral immunotherapy will be offered as part of a new standardised model of care in hospitals across the country. This world-first initiative aims to address the growing prevalence of peanut allergies among infants by providing a structured and controlled treatment protocol. The new approach is expected to significantly improve the quality of life for affected families and reduce the risk of severe allergic reactions. This landmark health initiative sets a new precedent in allergy treatment.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 50% • 25%
50-60% • 25%
60-70% • 25%
More than 70% • 25%
Less than 1% • 25%
1% to 5% • 25%
5% to 10% • 25%
More than 10% • 25%
0-50% • 25%
51-75% • 25%
76-90% • 25%
91-100% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% reduction • 25%
20% to 30% reduction • 25%
31% to 40% reduction • 25%
More than 40% reduction • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
More than 50% of major hospitals • 25%
25% to 50% of major hospitals • 25%
Less than 25% of major hospitals • 25%
Not adopted • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
21+ • 25%